- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133–2142. doi:10.1111/j.1743-6109.2009.01335.x.
- Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause. 2014;21(3):267–274. doi:10.1097/GME.0b013e3182976f46.
- Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1–7. doi:10.1016/j.ajog.2010.08.035.
- North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902. doi:10.1097/GME.0b013e3182a122c2.
- Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database System Rev. 2006;(4): CD001500. doi:10.1002/14651858.CD001500.pub2.
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8): CD001500. doi:10.1002/14651858.CD001500.pub3.
- Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer. 2005;41(17):2673–2681. doi:10.1016/j.ejca.2005.07.015.
- Mazzarello S, Hutton B, Ibrahim MFK, et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat. 2015;152(1):1–8. doi:10.1007/s10549-015-3434-z.
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–753. doi:10.1097/GME.0000000000000921.
- Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J. 2011;17(4):403–408. doi:10.1111/j.1524-4741.2011.01089.x.
- Kalogeraki A, Tamiolakis D, Relakis K, et al. Cigarette smoking and vaginal atrophy in postmenopausal women. In Vivo. 1996;10(6):597–600.
- Stika CS. Atrophic vaginitis. Dermatol Ther. 2010;23(5):514–522. doi:10.1111/j.1529-8019.2010.01354.x.
- Farrell R; American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice; American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. ACOG committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–e96. doi:10.1097/AOG.0000000000001351.
- Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66(1):43–73. doi:10.3322/caac.21319.
- Pritchard KI, Khan H, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ. 2002;166(8):1017–1022.
- Holmberg L, Anderson H; HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453–455. doi:10.1016/S0140-6736(04)15493-7.
- von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533–535. doi:10.1093/jnci/dji071.
- Birrer N, Chinchilla C, Del Carmen M, Dizon DS. Is hormone replacement therapy safe in women with a BRCA mutation? A systematic review of the contemporary literature. Am J Clin Oncol. 2018;41(3):313–315. doi:10.1097/COC.0000000000000269.
- Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55(2):103–115. doi:10.1016/j.maturitas.2006.05.004.
- Rebbeck TR, Friebel T, Wagner T, et al; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23(31):7804–7810. doi:10.1200/JCO.2004.00.8151.
- Kokot-Kierepa M, Bartuzi A, Kulik-Rechberger B, Rechberger T. [Local estrogen therapy—clinical implications—2012 update]. Ginekol Pol. 2012;83(10):772–777.
- Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncology. 2008;13(3):222–231. doi:10.1634/theoncologist.2007-0234.
- Pfeiler G, Glatz C, Königsberg R, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 2011;14(3):339–344. doi:10.3109/13697137.2010.529967.
- Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313–319. doi:10.1001/jamaoncol.2016.3904.
- Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144–148. doi:10.1200/JOP.2011.000352.
- Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–587. doi:10.1093/annonc/mdj127.
- Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603–609. doi:10.1007/s10549-012-2198-y.
- Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6(1):45–52. doi:10.1080/cmt.6.1.45.52.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 33, 2020 - Issue 3
Original Research
Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer
Amit L. JainDepartment of Internal Medicine, Division of Hematology Oncology, University of Tennessee Health Sciences Center, Memphis, Tennessee; Correspondence[email protected]
http://orcid.org/0000-0003-1668-2475
, MDhttp://orcid.org/0000-0003-1668-2475, , MD, , DO, Rana Muhammad UsmanDepartment of Internal Medicine, Division of Hematology Oncology, University of Tennessee Health Sciences Center, Memphis, Tennessee; http://orcid.org/0000-0003-0062-1811
, MDhttp://orcid.org/0000-0003-0062-1811, , MD, , MD, , MD, , RN, , BS, , MD, Harsha RanganathDepartment of Internal Medicine, Division of Hematology Oncology, University of Tennessee Health Sciences Center, Memphis, Tennessee; http://orcid.org/0000-0002-8661-6564
, MDhttp://orcid.org/0000-0002-8661-6564, , MD, Edward StepanskiVector Oncology, Memphis, Tennessee; http://orcid.org/0000-0002-1646-5094
, PhDhttp://orcid.org/0000-0002-1646-5094, , MD, Justin GatwoodDepartment of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennesseehttp://orcid.org/0000-0002-4801-8555
, PhDhttp://orcid.org/0000-0002-4801-8555 & , MD, PhD show all